InvestorsHub Logo
Followers 2
Posts 696
Boards Moderated 0
Alias Born 01/13/2001

Re: geob post# 28075

Sunday, 06/19/2005 12:38:53 PM

Sunday, June 19, 2005 12:38:53 PM

Post# of 82595
It seems a fair deal, Geo, if management provides the necessary means to "up" the value of the share price. I have been critical of their ability to do so these last couple of years. Confidence level has fallen to sub penny in Richards "hold 'em" possition w/ parcity of substantive PR's.

Most of my pessimism originated from the failed BioFrontera Deal which undercut those "secure pinnings" promised in the personalized medicine program promoted by Msrs. Gabriel. This seeming affiliation w/ PharmEco thru a subsidiary was viewed by investors a strong connection he brought to the Board. My subsequent view was equally influenced to the negative after it was revealed that although the pipeline products in their portfolio had viablility, the finacials were unsustainable. It would appear to me, even at this late date, that the money aspect would have been one of the first elements to consider in acquisitioning. It was during this time and for this purpose that I personally felt the LJG Commitment was made. As a shareholder, I feel duped in this regards and would hope that someone who attends the shareholder meeting addresses this aspect. Perhaps I my confused conclusions in this can be cleared up. I hope so, for if memory serves me, we had a substainable .05 pps level prior to this and it was the push for recognition w/ WSG, etc. that added to the upscale of debt ratio that is weighing DnaPrint down. From my limited viewpoint, we already had the necessary exposure in Forensics to bring in that present cash flow and Ancestery being promoted in their different areas could have been established w/out great expenditure. Like I have said, I am not a "bean counter" but our increased exposure hasn't done much for the bottom line.

Here it is at it's basic level for me. Whenever Dr. Frudakis speaks about technical advancements, I am opptomistically invigorated in my view of the potential value of my investment.
He is abreast in the R&D view, but I don't see where Richard has brought about the realization. Ok, I am impatient, but I can't see handing Richard a blank check based on his current history here.

Easy



Peace, Blessings & Boat Drinks, Easy